|
Device | Oncomine Dx Target Test |
Generic Name | Next generation sequencing oncology panel, somatic or germline variant detection system |
Applicant | LIFE TECHNOLOGIES CORPORATION 5781 VAN ALLEN WAY CARLSBAD, CA 92008 |
PMA Number | P160045 |
Supplement Number | S042 |
Date Received | 04/03/2023 |
Decision Date | 08/17/2023 |
Product Code |
PQP |
Advisory Committee |
Pathology |
Supplement Type | Normal 180 Day Track No User Fee |
Supplement Reason | Labeling Change - Indications/instructions/shelf life/tradename |
Expedited Review Granted? | No |
Combination Product | No |
Approval Order Statement Approval to include limitation in labelling. The updated labeling to include the statement: "Interference in variant calling can be observed at higher concentrations of chenodeoxycholic acid in cholangiocarcinoma (CC) clinical FFPE samples with IDH1 variants present at an allelic frequency near the limit of detection (LoD)." |